Innovation: Contain, Delay, Research, Mitigate

Innovation: Contain, Delay, Research, Mitigate

The UK, rather famously, adopted a four phase approach to the Covid-19 spread. One can argue that these phases should not have been seen as sequential, but run in parallel - the idea that 'research' would begin only after the 'failure' of the contain and delay phases, or that mitigation would wait until all three had run their course, seems odd to a strategist.

However, there is an interesting parallel to pharma - the first two phases rely on a 'prediction paradigm' where, because you know what is happening, you can make decisions. Waiting to pivot until you find out that you don't know is strategically unsound, because it is pretty certain that you do not know. This is true of pharma R&D that relies on the prediction paradigm.

This four phase approach is also an interesting metaphor for the way that corporate innovation happens to companies, if you'll allow the stretch that ideas are like viruses to stable companies. A group will be asked to investigate the idea, but their real goal (usually unconscious) is to contain it - perhaps confine it to the manufacturing group, the IT department... 'Containing' may be called 'owning' or 'championing', but both the group who take the idea in (who probably understand some of the idea, and also want to heroically carry it aloft) and the company (who really would prefer to get on with business as usual) will be very happy that it remains 'outside' and under investigation.

Whatever the strengths of the idea, the company will often then embark on a 'delay' phase. It won't be called that, as companies will find words like 'business case' or 'diligence' for the review, but it will certainly take its time to reach a decision maker.

No alt text provided for this image

?2020 Mike Rea

The Research phase will begin when it is clear that the idea won't follow that slow and steady path, but is being adopted elsewhere and is raising questions internally. Working groups, task forces and more will be set up to investigate - often ignoring the original group.

The Mitigation phase is perhaps the most interesting: trying to protect the core business from the new idea, and often the most creative - lots of reasons will be given for a 'not here' or 'we already tried that' or 'really, we're already doing it'.

While these observations are easy, the core of the challenge that I see lies in the way that 'innovation' is managed in most companies. It is either given its own department, where, like 'Digital', it is expected to have all of the ideas and somehow make the company adopt them, or to be the place that all new ideas are evaluated. Both of those strategies are bound to fail.

I remember being asked to 'judge' an innovation project at a company, where ideas were invited from the whole company. Unfortunately, the hard question that I asked next limited my engagement: how does one 'judge' an idea? And, who else is on the judging panel? As you'd expect, perhaps, the panel would be senior management plus me. Well, that was a recipe for a scenario where all 'ideas' would be ones that senior management understood, and were not threatened by - management does tend to prefer ideas that bring gentle change, and top down... The question of how one can 'judge' an idea was never addressed...

Innovation is systemic, systematic and cultural. Any company that treats ideas like viruses will delegate the response to its 'experts' - however, as so many have found during the pandemic, there are no experts with the whole picture. Understanding a 'digital' idea is one thing, for example, but understanding all of the impacts it could have on a company is another. To expect a siloed department to do so is clearly unrealistic, but it is exactly what most companies do.

The 'idea as virus' may seem a stretch, but just as 8-10% of the human genome is of viral origin, we see, in retrospect, that companies are rarely as uninfected by external ideas as they seem. They do make their way in, but it may make sense to revisit the strategy by which they're embraced or rejected - doing either more quickly would be a good start.

AMIR KALALI, MD

Physician-Scientist Leading at the Intersection of Life Sciences and Technology. Board Director, Executive Advisor, Investor, Curator of Communities

4 年

A very important topic that impacts the future of every company.

Joe Pimbley

Principal of Maxwell Consulting, LLC

4 年

"Ideas are like viruses to stable companies." Brilliant!

Alberto J Pacheco

Pharma/Biotech Consulting & Project Mgmt | GxP, Quality, Clin Ops, Vendor Oversight, Inspection Readiness, TMF

4 年

Sounds like IP strategy!

要查看或添加评论,请登录

Mike Rea的更多文章

  • Core Values: Skepticism and Unbiased Experimentation

    Core Values: Skepticism and Unbiased Experimentation

    The difference embedded in PureTech I went back to my interview with Daphne Zohar, the founder and CEO of PureTech…

    3 条评论
  • What if our answer is 5 slides, not 200?

    What if our answer is 5 slides, not 200?

    One thing I realized, watching back my interview on the Cures and Capital podcast was how simple some of the solutions…

    2 条评论
  • Which if am I thenning?

    Which if am I thenning?

    Better 'thens' require better 'ifs' If… then… We then ifs every day - if I take route A vs route B, then it will take…

    2 条评论
  • Rules for Pharma Revolutionaries

    Rules for Pharma Revolutionaries

    I always liked this video, but, judging by view count, I was in a small group… I do still believe in the need for…

    10 条评论
  • When is the right time to have a high Index of Suspicion?

    When is the right time to have a high Index of Suspicion?

    Independent, interdependent and in phase I..

    5 条评论
  • The large and the agile

    The large and the agile

    Explaining Lilly's current success..

  • Pharma's worst bet

    Pharma's worst bet

    The bet on pharma's traditional development model rarely pays off - time for a rethink Our industry is a strange one:…

    1 条评论
  • The Computer Science of Human Decisions

    The Computer Science of Human Decisions

    What can we learn from Algorithms to Live By? I’ve borrowed these 7 AI-generated lessons from Algorithms to Live By:…

    2 条评论
  • The best worst idea

    The best worst idea

    Premise, promise, proof It’s an alliterative phrase, that forms the basis for one of the worst positioning templates…

    3 条评论
  • The path to 100% Using probabilities the right way

    The path to 100% Using probabilities the right way

    A few years ago, I wrote the following article, Probabilities that aren't In it, I discussed the corrupting effect of…

    2 条评论

社区洞察

其他会员也浏览了